10975 N. Torrey Pines Road
59 articles with Epic Sciences
Large Prospective Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences' Platform to Predict Treatment Outcomes for Patients with Advanced Prostate Cancer
PROPHECY validation trial published in Journal of Clinical Oncology
Epic Sciences to Present at ASCO-GU 2019 New Data Demonstrating Utility of Liquid Biopsy to Optimize Drug Development
Epic Sciences, Inc. (Epic) announced today the presentation of four posters at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), held in San Francisco on February 14-16, 2019.
Epic Sciences, Inc. (Epic) announced today that they will be presenting new data on inter- and intra-patient phenotypic heterogeneity and the use of HER2 and AR expression in metastatic breast cancer circulating tumor cells at the 2018 San Antonio Breast Cancer Symposium (SABCS) from December 4 - 8 in San Antonio, TX.
Epic Sciences Joins Forces with Canadian Consortium of Investigators to Predict Late Recurrence of Metastatic Breast Cancer
Epic Sciences ("Epic"), is collaborating with four major breast cancer centers on a clinical trial to determine if Epic's blood test can be used to predict which women, who have already been treated for localized breast cancer, are at risk of late recurrence of metastatic breast cancer.
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective December 10
Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage
Blue Ox Healthcare Partners, LLC (“Blue Ox” or the “Firm”), an investment firm focused on providing growth capital to healthcare companies in the middle market, today announced that it led a $52 million Series E investment in Epic Sciences, Inc.
Epic Sciences Presents Detection and Characterization of Rare Peripheral CTC Immunogenicity and T-Cell Activation
Data demonstrated the company's "No Cell Left Behind" detection platform's capability to analyze potential markers of response to immuno-oncology agents.
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
Medicare Draft Coverage Supports Clinical Utility of the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Medicare Patients with Coverage Once LCD Is Finalized
Epic Sciences to Present Single Cell PSMA Analysis to Provide Insight Into Tumor Heterogeneity and Links to Response With Anti-PSMA Therapy
Within patient samples, single cell analysis showed that PSMA expression was heterogeneous from cell to cell demonstrating the complexity of target expression.
The Epic breast cancer panel is the most comprehensive breast cancer biomarker panel available for CTCs within a blood sample.
Epic Sciences adds simultaneous MSI and CIN measurements, also known as genomic scarring analysis, to the single cell NGS workflow for clinical research of immuno-oncology therapies.
Epic Sciences Release: Liquid Biopsy Test Identifies Androgen Receptor Protein Expression In Circulating Tumor Cells In Women With Metastatic Breast Cancer
Epic Sciences Release: Liquid Biopsy Tumor Heterogeneity Test Predicts Resistance To Targeted Therapy In Metastatic Prostate Cancer Patients
Epic Sciences And Collaborators Publish Study On New Blood Test Showing Expression Of PD-L1 On Circulating Cells Is Associated With Worse Outcomes In Lung Cancer Patients Not Treated With PD-1 Inhibitors
Study From Memorial Sloan-Kettering Cancer Center And Epic Sciences Shows Only Nuclear-Localized AR-V7 Is Predictive Of Therapy Benefit For Patients With Metastatic Prostate Cancer
Genomic Health, Inc. And Epic Sciences Announce Strategic Collaboration To Deliver Novel AR-V7 Liquid Biopsy Test To Predict Treatment Response In Metastatic Prostate Cancer